logo
Plus   Neg
Share
Email

Novavax Reports Positive Phase 1 Data For NVX-CoV2373 - Quick Facts

Novavax, Inc. (NVAX) said, NVX-CoV2373, the company's recombinant COVID-19 vaccine candidate adjuvanted with Matrix-M, was generally well-tolerated and elicited robust antibody responses numerically superior to that seen in human convalescent sera in phase 1 portion of the Phase 1/2 clinical trial. The study was conducted in 131 healthy adults ages 18-59 years. All subjects developed anti-spike IgG antibodies after a single dose of vaccine, many of them also developing wild-type virus neutralizing antibody responses, and after dose 2, 100% of participants developed wild-type virus neutralizing antibody responses.

"The Phase 1 data demonstrate that NVX-CoV2373 with our Matrix-M adjuvant is a well-tolerated COVID-19 vaccine with a robust immunogenicity profile," said Gregory Glenn, President, Research and Development at Novavax.

The trial was supported by funding from the Coalition for Epidemic Preparedness Innovations and was conducted at two sites in Australia.

Shares of Novavax were up more than 10% after hours.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
U.S. tech giant Google is laying the groundwork for a fiber-optic network that will connect the first time through Saudi Arabia and Israel, opening a new global internet traffic corridor, the Wall Street Journal reported, citing people familiar with the plans. The link would be established as part of an optical-fiber cable line connecting Europe with India. U.S. retailers Best Buy Co. Inc., Abercrombie & Fitch Co., and Dollar Tree Inc. on Tuesday reported results for the third quarter that surpassed analysts' expectations. The upbeat results indicate that retailers have largely recovered from the impact of the coronavirus pandemic just as the holiday season approaches. The companies have also intensified their focused on digital sales. The U.S. Food and Drug Administration approved the first drug to treat primary hyperoxaluria type 1 (PH1), an ultra-rare genetic disorder which causes recurrent kidney stones and loss of kidney function. Alnylam Pharmaceuticals' Oxlumo (lumasiran) in the form of injection lowers urinary oxalate levels in pediatric and adult patients.
Follow RTT